Effect of aspirin, other NSAIDs, and statins on PSA and PSA velocity

Amit M. Algotar, Patricia A. Thompson, James Ranger-Moore, M. Suzanne Stratton, Chiu-Hsieh Hsu, Frederick R Ahmann, Raymond B Nagle, Steven P Stratton

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

BACKGROUND. Aspirin, other non-steroidal anti-inflammatory drugs (NSAIDs), and statins have been associated with lower risk of prostate cancer and its progression, though results have been inconsistent. METHODS. Data from 140 men with prostate cancer enrolled in a Phase 2 clinical trial of selenium to prevent prostate cancer progression were analyzed to determine association between aspirin, other NSAIDs, or statin use with baseline serum prostate-specific antigen (PSA) levels and PSA velocity (rate of PSA change over time) using repeated measures over an average follow-up time of 3.2 years. Multiple linear regression and mixed effects models were used to model the association of medication use with PSA at baseline and with PSA velocity, respectively. RESULTS. Baseline PSA levels were significantly lower in aspirin users compared to non-users (5.17 ng/ml vs. 7.58 ng/ml, P=0.001). This association was statistically significant in never smokers (aspirin users vs. non-users: 4.19 ng/ml vs. 8.24 ng/ml, P=0.004) but not in ever smokers (aspirin users vs. non-users: 5.52 ng/ml vs. 7.3 ng/ml, P=0.101). Statin and other NSAID use was not associated with baseline PSA. Aspirin, statin, or other NSAID use at baseline demonstrated a non-significant negative association with PSA velocity. CONCLUSION. These findings support an effect of aspirin use on PSA, particularly among never smokers. However, they do not suggest a protective effect on the disease and support previous findings that aspirin use may mask accurate measurement of PSA warranting consideration of washout procedures prior to testing.

Original languageEnglish (US)
Pages (from-to)883-888
Number of pages6
JournalProstate
Volume70
Issue number8
DOIs
StatePublished - Jun 1 2010

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Prostate-Specific Antigen
Aspirin
Anti-Inflammatory Agents
Pharmaceutical Preparations
Prostatic Neoplasms
Masks
Selenium
Linear Models
Clinical Trials

Keywords

  • Aspirin
  • NSAID
  • PSA
  • PSA velocity
  • Statin

ASJC Scopus subject areas

  • Urology
  • Oncology
  • Medicine(all)

Cite this

Effect of aspirin, other NSAIDs, and statins on PSA and PSA velocity. / Algotar, Amit M.; Thompson, Patricia A.; Ranger-Moore, James; Stratton, M. Suzanne; Hsu, Chiu-Hsieh; Ahmann, Frederick R; Nagle, Raymond B; Stratton, Steven P.

In: Prostate, Vol. 70, No. 8, 01.06.2010, p. 883-888.

Research output: Contribution to journalArticle

Algotar AM, Thompson PA, Ranger-Moore J, Stratton MS, Hsu C-H, Ahmann FR et al. Effect of aspirin, other NSAIDs, and statins on PSA and PSA velocity. Prostate. 2010 Jun 1;70(8):883-888. https://doi.org/10.1002/pros.21122
Algotar, Amit M. ; Thompson, Patricia A. ; Ranger-Moore, James ; Stratton, M. Suzanne ; Hsu, Chiu-Hsieh ; Ahmann, Frederick R ; Nagle, Raymond B ; Stratton, Steven P. / Effect of aspirin, other NSAIDs, and statins on PSA and PSA velocity. In: Prostate. 2010 ; Vol. 70, No. 8. pp. 883-888.
@article{37969afce54349749d376be3ae0e8655,
title = "Effect of aspirin, other NSAIDs, and statins on PSA and PSA velocity",
abstract = "BACKGROUND. Aspirin, other non-steroidal anti-inflammatory drugs (NSAIDs), and statins have been associated with lower risk of prostate cancer and its progression, though results have been inconsistent. METHODS. Data from 140 men with prostate cancer enrolled in a Phase 2 clinical trial of selenium to prevent prostate cancer progression were analyzed to determine association between aspirin, other NSAIDs, or statin use with baseline serum prostate-specific antigen (PSA) levels and PSA velocity (rate of PSA change over time) using repeated measures over an average follow-up time of 3.2 years. Multiple linear regression and mixed effects models were used to model the association of medication use with PSA at baseline and with PSA velocity, respectively. RESULTS. Baseline PSA levels were significantly lower in aspirin users compared to non-users (5.17 ng/ml vs. 7.58 ng/ml, P=0.001). This association was statistically significant in never smokers (aspirin users vs. non-users: 4.19 ng/ml vs. 8.24 ng/ml, P=0.004) but not in ever smokers (aspirin users vs. non-users: 5.52 ng/ml vs. 7.3 ng/ml, P=0.101). Statin and other NSAID use was not associated with baseline PSA. Aspirin, statin, or other NSAID use at baseline demonstrated a non-significant negative association with PSA velocity. CONCLUSION. These findings support an effect of aspirin use on PSA, particularly among never smokers. However, they do not suggest a protective effect on the disease and support previous findings that aspirin use may mask accurate measurement of PSA warranting consideration of washout procedures prior to testing.",
keywords = "Aspirin, NSAID, PSA, PSA velocity, Statin",
author = "Algotar, {Amit M.} and Thompson, {Patricia A.} and James Ranger-Moore and Stratton, {M. Suzanne} and Chiu-Hsieh Hsu and Ahmann, {Frederick R} and Nagle, {Raymond B} and Stratton, {Steven P}",
year = "2010",
month = "6",
day = "1",
doi = "10.1002/pros.21122",
language = "English (US)",
volume = "70",
pages = "883--888",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "8",

}

TY - JOUR

T1 - Effect of aspirin, other NSAIDs, and statins on PSA and PSA velocity

AU - Algotar, Amit M.

AU - Thompson, Patricia A.

AU - Ranger-Moore, James

AU - Stratton, M. Suzanne

AU - Hsu, Chiu-Hsieh

AU - Ahmann, Frederick R

AU - Nagle, Raymond B

AU - Stratton, Steven P

PY - 2010/6/1

Y1 - 2010/6/1

N2 - BACKGROUND. Aspirin, other non-steroidal anti-inflammatory drugs (NSAIDs), and statins have been associated with lower risk of prostate cancer and its progression, though results have been inconsistent. METHODS. Data from 140 men with prostate cancer enrolled in a Phase 2 clinical trial of selenium to prevent prostate cancer progression were analyzed to determine association between aspirin, other NSAIDs, or statin use with baseline serum prostate-specific antigen (PSA) levels and PSA velocity (rate of PSA change over time) using repeated measures over an average follow-up time of 3.2 years. Multiple linear regression and mixed effects models were used to model the association of medication use with PSA at baseline and with PSA velocity, respectively. RESULTS. Baseline PSA levels were significantly lower in aspirin users compared to non-users (5.17 ng/ml vs. 7.58 ng/ml, P=0.001). This association was statistically significant in never smokers (aspirin users vs. non-users: 4.19 ng/ml vs. 8.24 ng/ml, P=0.004) but not in ever smokers (aspirin users vs. non-users: 5.52 ng/ml vs. 7.3 ng/ml, P=0.101). Statin and other NSAID use was not associated with baseline PSA. Aspirin, statin, or other NSAID use at baseline demonstrated a non-significant negative association with PSA velocity. CONCLUSION. These findings support an effect of aspirin use on PSA, particularly among never smokers. However, they do not suggest a protective effect on the disease and support previous findings that aspirin use may mask accurate measurement of PSA warranting consideration of washout procedures prior to testing.

AB - BACKGROUND. Aspirin, other non-steroidal anti-inflammatory drugs (NSAIDs), and statins have been associated with lower risk of prostate cancer and its progression, though results have been inconsistent. METHODS. Data from 140 men with prostate cancer enrolled in a Phase 2 clinical trial of selenium to prevent prostate cancer progression were analyzed to determine association between aspirin, other NSAIDs, or statin use with baseline serum prostate-specific antigen (PSA) levels and PSA velocity (rate of PSA change over time) using repeated measures over an average follow-up time of 3.2 years. Multiple linear regression and mixed effects models were used to model the association of medication use with PSA at baseline and with PSA velocity, respectively. RESULTS. Baseline PSA levels were significantly lower in aspirin users compared to non-users (5.17 ng/ml vs. 7.58 ng/ml, P=0.001). This association was statistically significant in never smokers (aspirin users vs. non-users: 4.19 ng/ml vs. 8.24 ng/ml, P=0.004) but not in ever smokers (aspirin users vs. non-users: 5.52 ng/ml vs. 7.3 ng/ml, P=0.101). Statin and other NSAID use was not associated with baseline PSA. Aspirin, statin, or other NSAID use at baseline demonstrated a non-significant negative association with PSA velocity. CONCLUSION. These findings support an effect of aspirin use on PSA, particularly among never smokers. However, they do not suggest a protective effect on the disease and support previous findings that aspirin use may mask accurate measurement of PSA warranting consideration of washout procedures prior to testing.

KW - Aspirin

KW - NSAID

KW - PSA

KW - PSA velocity

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=77952318028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952318028&partnerID=8YFLogxK

U2 - 10.1002/pros.21122

DO - 10.1002/pros.21122

M3 - Article

C2 - 20135645

AN - SCOPUS:77952318028

VL - 70

SP - 883

EP - 888

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 8

ER -